Shots:
GentiBio to receive undisclosed upfront cash & is eligible to receive ~$1.9B in development & commercial milestones along with royalties. The collaboration will combine GentiBio’s Treg platform with BMS’ cell therapies & immunology leadership
Through the extended partnership, the Treg platform will be applied to produce stable & disease-specific engineered Tregs against multiple targets whereas BMS will receive the right to develop & advance 3 of the resulting programs into clinical trials for IBD patients
GentiBio’s Treg platform is a T cell platform that generates highly selective & durable Tregs with the potential to suppress inflammation & autoimmune dysfunction
Ref: PR Newswire | Image: BMS
